Navigation Links
Pak1 expression increases tamoxifen resistance in breast cancer patients

A protein that activates estrogen receptors in breast cancer may play a role in resistance to therapeutic effects of anti-estrogen tamoxifen treatment, according to a study in the May 17 Journal of the National Cancer Institute.

Pak 1 is a member of a family of proteins involved in many cell functions, such as gene expression, cell movement, and cell death. Previous studies have suggested that the presence of this protein may lead to more invasive breast cancer.

Goran Landberg, M.D., Lund University in Malmö, Sweden, and colleagues examined Pak1 expression in 403 premenopausal women with breast cancer. The women participated in a clinical trial where they were randomly assigned to receive tamoxifen therapy or no treatment. The authors examined whether tumor levels of Pak1 were associated with the women's chances of breast cancer recurrence and the effects of tamoxifen therapy.

The authors found that increased Pak1 expression was associated with increased resistance to tamoxifen therapy for women with estrogen receptor positive breast cancer. Patients with ER-positive tumors and low levels of Pak1 had longer survival without tumor recurrence than patients who did not receive treatment. Overexpression of certain types of Pak1 was associated with decreased response to tamoxifen therapy.

The authors write, "Overall, our observations suggest that Pak1 activation and nuclear localization contribute to the reduced tamoxifen sensitivity that has been observed in some breast tumor cells. Therapies that target Pak1 expression or activity may therefore represent a strategy to increase the endocrine treatment response in breast cancer."

In an accompanying editorial, V. Craig Jordan, Ph.D., D.Sc., of Fox Chase Cancer Center in Philadelphia, discusses what is known about resistance to tamoxifen therapy. He writes, "The clinical correlations reported by Holm et al. indicate that packing tumor cell nuclei with Pak can perturb t amoxifen's action. The tumor, once "Paked up", has no alternative but to grow."


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Alcohols effects on gene expression in the central nervous system
2. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
3. Towards precise classification of cancers based on robust gene functional expression profiles
4. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
5. Study: homemade gene expression technology unreliable
6. Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression
7. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays
8. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
9. Computational verification of protein-protein interactions by orthologous co-expression
10. Random gene expression may drive HIV into hiding
11. Confirmation of human protein interaction data by human expression data
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology: